Table 1. Patient demographics and baseline characteristics.

Notes: *reported as mean ± SD; **Includes one patient who also received sorafenib

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine transaminase; AST, aspartate aminotransferase; INR, international normalized ratio; MWA, microwave ablation; TACE, transarterial chemoembolization

Demographic or Characteristic
Mean age ± SD (range)	65.5±7.5 (52-90)
Male sex	32 (100%)
Ethnicity
Ethnicity - Non-Hispanic	17 (53.1%)
Ethnicity - Hispanic	15 (46.9%)
Liver disease etiology
Hepatitis	24 (75.0%)
Alcohol	20 (62.5%)
Non-alcoholic fatty liver disease	1 (3.1%)
Other liver disease-related pathologies
Portal hypertension	24 (75.0%)
Varices	17 (62.5%)
Encephalopathy	15 (46.9%)
Ascites	8 (25.0%)
Laboratory testing*
Serum albumin, g/dL	1.5 ± 0.8
Total bilirubin, mg/dL	3.2 ± 0.5
INR	1.3 ± 0.2
AST (units/L)	75.6 ± 60.9
ALT (unit/L)	49.2 ± 38.1
Creatinine (mg/dl)	1.0 ± 0.5
AFP (ng/mL)	622.3 ± 1083.7
Tumor size (cm)*
All tumors	4.1 ± 2.9
Primary tumors	4.6 ± 3.1
Secondary tumors (n=13)	2.4 ± 1.2
Previous treatments
TACE only**	5 (15.6%)
MWA only	5 (15.6%)
TACE + MWA**	4 (12.5%)